Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Decreased Expression of Programmed Death Ligand-L1 by Seven in Absentia Homolog 2 in Cholangiocarcinoma Enhances T-Cell–Mediated Antitumor Activity

27 Jan 2022

Abstract excerpt

N6-methyladenosine (m6A) has been reported as an important mechanism of post-transcriptional regulation. Programmed death ligand 1 (PD-L1) is a primary immune inhibitory molecule expressed on tumor cells that promotes immune evasion. In addition, seven in absentia homolog 2 (Siah2), a RING E3 ubiquitin ligase, has been involved in tumorigenesis and cancer progression. However, the role of m6A-METTL14-Siah2-PD-L1...

Topics

Join the communities discussing this publication.

Cholangiocarcinoma and Gallbladder Cancer Studies
Peptidase Inhibition and Analysis
RNA modifications and cancer

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 35154166
DOI: 10.3389/fimmu.2022.845193

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Decreased Expression of Programmed Death Ligand-L1 by Seven in Absentia Homolog 2 in Cholangiocarcinoma Enhances T-Cell–Mediated Antitumor ActivityPMID 35154166Read ↗

M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic CholangiocarcinomaSemantic proximity Read ↗

Development of N6-methyladenosine Related Signature as New Biomarker for Prognosis of Hepatocellular Carcinoma and Correlates with Sorafenib and anti-PD-1 Immunotherapy Treatment ResponseSemantic proximity Read ↗

Significance of m 6A Methyltransferase‑Related lncRNAs in the Prognosis and Immunotherapy of Hepatocellular CarcinomaSemantic proximity Read ↗

Systematic analysis of the expression profile and prognostic significance of m6A regulators and PD-L1 in hepatocellular carcinomaSemantic proximity Read ↗

AMDHD1 acts as a tumor suppressor and contributes to activation of TGF-β signaling pathway in cholangiocarcinomaSemantic proximity Read ↗

ACAA2 was a predictor for the prognosis and immunotherapy response of hepatocellular carcinomaSemantic proximity Read ↗

Siah1 in cancer and nervous system diseases (Review)Semantic proximity Read ↗

Aberrant DNA Methylation in CholangiocarcinomaSemantic proximity Read ↗

Nuclear accumulation of seven in absentia homologue‐2 supports motility and proliferation of liver cancer cellsSemantic proximity Read ↗

Exploring the role of NAA40 in immune infiltrates and prognostic prediction in hepatocellular carcinomaSemantic proximity Read ↗

m5C and m6A modification of long noncoding NKILA accelerates cholangiocarcinoma progression via the miR‐582‐3p‐YAP1 axisSemantic proximity Read ↗

METTL16 predicts a favorable outcome and primes antitumor immunity in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.